The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*^†

REFERENCES

• Eddershaw P.J., Beresford A.P., Bayliss M.K. ADME/PK as Part of a Rational Approach to Drug Discovery. Drug Discovery Today 2000; 5: 409–414
   PubMed Web of Science ®Google Scholar
• Riley R.J. The Potential Pharmacological and Toxicological Impact of P450 Screening. Curr. Opin. Drug Discovery Dev. 2001; 4: 45–54
   PubMedGoogle Scholar
• Obach R.S. The Prediction of Human Clearance from Hepatic Microsomal Metabolism Data. Curr. Opin Drug Discovery Dev. 2001; 4: 36–44
   PubMedGoogle Scholar
• Fisher M.B., Campanale K., Ackermann B.L., VandenBranden M., Wrighton S.A. In Vitro Glucuronidation Using Human Liver Microsomes and the Pore-Forming Peptide Alamethicin. Drug Metab. Dispos. 2000; 28: 560–566
   PubMed Web of Science ®Google Scholar
• Meech R., Mackenzie P.I. Structure and Function of Uridinediphosphate Glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol. 1997; 24: 907–915
   PubMed Web of Science ®Google Scholar
• Miners J.O., Mackenzie P.I. Drug Glucuronidation in Humans. Pharmacol Ther. 1991; 51: 347–369
   PubMed Web of Science ®Google Scholar
• Radominska-Pandya A., Czernik P.J., Little J.M., Battaglia E., Mackenzie P.I. Structural and Functional Studies of UDP-Glucuronosyltransferases. Drug Metab. Rev. 1999; 31: 817–899
   PubMed Web of Science ®Google Scholar
• Mackenzie P.I., Owens I.S., Burchell B., Bock K.W., Bairoch A., Belanger A., Fournel-Gigleux S., Green M., Hum D.W., Iyanagi T., Lancet D., Louisot P., Magdalou J., Chowdhury J.R., Ritter J.K., Schachter H., Tephly T.R., Tipton K.F., Nebert D.W. The UDP-Glycosyltransferase Gene Superfamily: Recommended Nomenclature Update Based on Evolutionary Divergence. Pharmacogenetics 1997; 7: 255–269
   PubMedGoogle Scholar
• Tukey R.H., Strassburg C.P. Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease. Annu. Rev. Pharmacol. Toxicol. 2000; 40: 581–616
   PubMed Web of Science ®Google Scholar
• Ritter J.K. Roles of Glucuronidation and UDP-Glucuronosyltransferases in Xenobiotic Bioactivation Reactions. Chem. Biol. Interact. 2000; 129: 171–193
   PubMed Web of Science ®Google Scholar
• Rowland M., Tozer T.N. Clinical Pharmacokinetics: Concepts and Applications. 3rd Ed, Williams and Wilkins, Media, PA 1995
   Google Scholar
• Hanninen O., Alanen K. The Competitive Inhibition of p-Nitrophenyl-β-d-Glucopyranosiduronic Acid Synthesis by Aliphatic Alcohols In Vitro. Biochem. Pharmacol. 1966; 15: 1465–1467
   PubMed Web of Science ®Google Scholar
• Yokota H., Ando F., Iwano H., Yuasa A. Inhibitory Effects of Uridine Diphosphate on UDP-Glucuronosyltransferase. Life Sci. 1998; 63: 1693–1699
   PubMed Web of Science ®Google Scholar
• Bechinger B. Structure and Functions of Channel-Forming Peptides: Magainins, Cecropins, Melittin, and Alamethicin. J. Membr. Biol. 1997; 156: 197–211
   PubMed Web of Science ®Google Scholar
• Wang T.-F., Guidotti G. Golgi Localization and Functional Expression of Human Uridine Diphosphatase. J. Biol. Chem. 1998; 273: 11392–11399
   PubMed Web of Science ®Google Scholar
• Puskas F., Braun L., Csala M., Kardon T., Marcolongo P., Benedetti A., Mandl J., Banhegyi G. Gulonolactone Oxidase Activity-Dependent Intravesicular Glutathione Oxidation in Rat Liver Microsomes. FEBS Lett. 1998; 430: 293–296
   PubMed Web of Science ®Google Scholar
• Banhegyi G., Csala M., Mand J., Burchell A., Burchell B., Marcolongo P., Fulceri R., Benedetti A. Fatty Acyl-CoA Esters and the Permeability of Rat Liver Microsomal Vesicles. Biochem. J. 1996; 320: 343–344
   PubMed Web of Science ®Google Scholar
• Banhegyi G., Marcolongo P., Fulceri R., Hinds C., Burchell A., Benedetti A. Demonstration of a Metabolically Active Glucose-6-Phosphate Pool in the Lumen of Liver Microsomal Vesicles. J. Biol. Chem. 1997; 272: 13584–13590
   PubMed Web of Science ®Google Scholar
• Vanstapel F., Blanckaert N. Topology and Regulation of Bilirubin UDP-Glucuronyltransferase in Sealed Native Microsomes from Rat Liver. Arch. Biochem. Biophys. 1988; 263: 216–225
   PubMed Web of Science ®Google Scholar
• Banhegyi G., Bellomo G., Fulceri R., Mandl J., Benedetti A. Intralumenal Calcium of the Liver Endoplasmic Reticulum Stimulates the Glucuronidation of p-Nitrophenol. Biochem. J. 1993; 292: 99–104
   PubMed Web of Science ®Google Scholar
• Little J.M., Lehman P.A., Nowell S., Samokyszyn V., Radominska A. Glucuronidation of all-trans-Retinoic Acid and 5,6-Epoxy-all-trans-Retinoic Acid. Drug Metab. Dispos. 1997; 25: 5–11
   PubMed Web of Science ®Google Scholar
• Fulceri R., Banhegyi G., Gamberucci A., Giunti R., Mandl J., Benedetti A. Evidence for the Intraluminal Positioning of p-Nitrophenol UDP-Glucuronosyltransferase Activity in Rat Liver Microsomal Vesicles. Arch. Biochem. Biophys. 1994; 309: 43–46
   PubMed Web of Science ®Google Scholar
• Zakim, D.; Goldenberg, J.; Vessey, D. A. Effects of Metals on the Properties of Hepatic Microsomal Uridine Diphosphate Glucuronyltransferase. Biochemistry 1973, 12, 4068–4074.
   Google Scholar
• Yamamura N., Imura-Miyoshi K., Naganuma H. Panipenum, a Carbapenem Antibiotic, Increases the Level of Hepatic UDP-Glucuronic Acid in Rats. Drug Metab. Dispos. 2000; 28: 1484–1486
   PubMed Web of Science ®Google Scholar
• Sugiyama T., Goldman W.F. Measurement of SR Free Ca and Mg in Permeabilized Smooth Muscle Cells with Use of Furaptra. Am. J. Physiol. 1995; 269: C698–C705
   PubMed Web of Science ®Google Scholar
• Kim J.H., Johannes L., Goud B., Antony C., Lingwood C.A., Daneman R., Grinstein S. Noninvasive Measurement of the pH of the Endoplasmic Reticulum at Rest and During Calcium Release. Proc. Natl Acad. Sci. USA 1998; 95: 2997–3002
   PubMed Web of Science ®Google Scholar
• Yu W., Enriquez P. LC/MS/MS Analysis of Drug Conjugates: A Potential Error Source for Quantitation also Provides a Means for Assessing Drug Absorption. ISSX Proc. 1999; 15: 234
   Google Scholar
• Coffman B.L., Rios G.R., King C.D., Tephly T.R. Human UGT2B7 Catalyzes Morphine Glucuronidation. Drug Metab. Dispos. 1997; 25: 1–4
   PubMed Web of Science ®Google Scholar
• Senafi S.B., Clarke D.J., Burchell B. Investigation of the Substrate Specificity of a Cloned Expressed Human Bilirubin UDP-Glucuronosyltransferase: UDP Sugar Specificity and Involvement in Steroid and Xenobiotic Glucuronidation. Biochem. J. 1994; 303: 233–240
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U., Mey U., Green M.D., Tephly T.R. Comparative N-Glucuronidation Kinetics of Ketotifen and Amitryptyline by Expressed Human UDP-Glucuronosyltransferases and Liver Microsomes. Drug Metab. Dispos. 2000; 28: 869–872
   PubMed Web of Science ®Google Scholar
• Strassburg C.P., Kneip S., Topp J., Obermayer-Straub P., Barut A., Tukey R.H., Manns M.P. Polymorphic Gene Regulation and Interindividual Variation of UDP-Glucuronosyltransferase Activity in Human Small Intestine. J. Biol. Chem. 2000; 275: 36164–36171
   PubMed Web of Science ®Google Scholar
• McGurk K.A., Brierley C.H., Burchell B. Drug Glucuronidation by Human Renal UDP-Glucuronosyltransferases. Biochem. Pharmacol. 1998; 55: 1005–1012
   PubMed Web of Science ®Google Scholar
• Thummel K.E., Kunze K.L., Shen D.D. Enzyme-Catalyzed Processes of First-Pass Hepatic and Intestinal Drug Extraction. Adv. Drug Deliv. Rev. 1997; 27: 99–127
   PubMed Web of Science ®Google Scholar
• Fisher M.B., VandenBranden M., Findlay K., Burchell B., Thummel K.E., Hall S.D., Wrighton S.A. Tissue Distribution and Interindividual Variation in Human UDP-Glucuronosyltransferase Activity: Relationship Between UGT1A1 Promoter Genotype and Variability in a Liver Bank. Pharmacogenetics 2000; 10: 727–739
   PubMedGoogle Scholar
• Czernick P.J., Little J.M., Barone G.W., Raufman J.-P., Radominska-Pandya A. Glucuronidation of Estrogens and Retinoic Acid and Expression of UDP-Glucuronosyltransferase 2B7 in Human Intestinal Mucosa. Drug Metab. Dispos. 2000; 28: 1210–1216
   PubMed Web of Science ®Google Scholar
• Paine M.F., Fisher M.B. Immunochemical Identification of UGT Isoforms in Human Small Bowel and in Caco-2 Cell Monolayers. Biochem. Biophys. Res. Commun. 2000; 273: 1053–1057
   PubMed Web of Science ®Google Scholar
• Radominska-Pandya A., Little J.M., Pandya J.T., Tephly T.R., King C.D., Barone G.W., Raufman J.-P. UDP-Glucuronosyltransferases in Human Intestinal Mucosa. Biochim. Biophys. Acta 1998; 1394: 199–208
   PubMed Web of Science ®Google Scholar
• Veroli P., O'Kelly B., Bertrand F., Trouvin J.H., Farinotti R., Ecoffey C. Extrahepatic Metabolism of Propofol in Man During the Anhepatic Phase of Orthotopic Liver Transplantation. Br. J. Anaesth. 1992; 68: 183–186
   PubMed Web of Science ®Google Scholar
• Raoof A.A., van Obbergh L.J., de Ville de Goyet J., Verbeeck R.K. Extrahepatic Glucuronidation of Propofol in Man: Possible Contribution of Gut Wall and Kidney. Eur. J. Clin. Pharmacol. 1996; 50: 91–96
   PubMed Web of Science ®Google Scholar
• Cheng Z., Radominska-Pandya A., Tephly T.R. Studies on the Substrate Specificity of Human Intestinal UDP-Glucuronosyltransferases 1A8 and 1A10. Drug Metab. Dispos. 1999; 27: 1165–1170
   PubMed Web of Science ®Google Scholar
• Ethell B.T., Beaumont K., Rance D.J., Burchell B. Use of Cloned and Expressed Human UDP-Glucuronosyltransferases for the Assessment of Human Drug Conjugation and Identification of Potential Drug Interactions. Drug Metab. Dispos. 2001; 29: 48–53
   PubMed Web of Science ®Google Scholar
• Fisher J.M., Wrighton S.A., Watkins P.B., Schmedlin-Ren P., Calamia J.C., Shen D.D., Kunze K.L., Thummel K.E. First-Pass Midazolam Metabolism Catalyzed by 1α,25-Dihydroxy Vitamin D3-Modified Caco-2 Cell Monolayers. J. Pharm. Exp. Ther. 1999; 289: 1134–1142
   PubMed Web of Science ®Google Scholar
• Paine M.F., Schmedlin-Ren P., Watkins P.B. Drug Metab. Dispos. 1999; 27: 360–364
   PubMed Web of Science ®Google Scholar
• Ritter J.K., Kessler F.K., Thompson M.T., Grove A.D., Auyeung D.J., Fisher R.A. Expression and Inducibility of the Human Bilirubin UDP-Glucuronosyltransferase UGT1A1 in Liver and Cultured Primary Hepatocytes: Evidence for Both Genetic and Environmental Influences. Hepatology 1999; 30: 476–484
   PubMed Web of Science ®Google Scholar
• Yue Q., Odar-Cederlof I., Svensson J.-O., Sawe J. Glucuronidation of Morphine in Human Kidney. Pharmacol. Toxicol. 1988; 63: 337–341
   PubMedGoogle Scholar
• Yue Q., von Bahr C., Odar-Cederlof I., Sawe J. Glucuronidation of Codeine and Morphine in Human Liver and Kidney Microsomes: Effect of Inhibitors. Pharmacol. Toxicol. 1990; 66: 221–226
   PubMedGoogle Scholar
• Brunelle F.M., Verbeeck R.K. Glucuronidation of Diflunisal in Liver and Kidney Microsomes of Rat and Man. Xenobiotica 1996; 26: 123–131
   PubMed Web of Science ®Google Scholar
• Vietri M., Pietrabissa A., Mosca F., Pacifici G.M. Mycophenolic Acid Glucuronidation and Its Inhibition by Non-steroidal Anti-Inflammatory Drugs in Liver and Kidney. Eur. J. Clin. Pharmacol. 2000; 56: 659–664
   PubMed Web of Science ®Google Scholar
• Little J.M., Lester R., Kuipers F., Vonk R., Mackenzie P.I., Drake R.R., Frame L., Radominska-Pandya A. Variability of Human Hepatic UDP-Glucuronosyltransferase Activity. Acta Biochim. Pol. 1999; 46: 351–363
   PubMed Web of Science ®Google Scholar
• Lacarelle B., Rajaonarison J.F., Gauthier T., Placidi M., Catalin J., Rahmani R. Use of a Human Liver Bank in Drug Glucuronidation Studies. Toxicol. In Vitro 1991; 5: 559–562
   PubMed Web of Science ®Google Scholar
• Burchell B., Soars M., Monaghan G., Cassidy A., Smith D., Ethell B. Drug-Mediated Toxicity Caused by Genetic Deficiency of UDP-Glucuronosyltransferases. Toxicol. Lett. 2000; 112–113: 333–340
   PubMed Web of Science ®Google Scholar
• Mackenzie P.I., Miners J.O., McKinnon R.A. Polymorphisms in UDP-Glucuronosyltransferase Genes: Functional Consequences and Clinical Relevance. Clin. Chem. Lab. Med. 2000; 38: 889–892
   PubMed Web of Science ®Google Scholar
• Beutler E., Gelbart T., Demina A. Racial Variability in the UDP-Glucuronosyltransferase 1 (UGT1A1) Promoter: a Balanced Polymorphism for Regulation of Bilirubin Metabolism?. Proc. Natl Acad. Sci. USA 1998; 95: 8170–8174
   PubMed Web of Science ®Google Scholar
• Monaghan G., Ryan M., Seddon R., Hume R., Burchell B. Genetic Variation in Bilirubin UDP-Glucuronosyltransferase Gene Promoter and Gilbert's Syndrome. Lancet 1996; 347: 578–581
   PubMed Web of Science ®Google Scholar
• Burchell B., Hume R. Molecular Genetic Basis of Gilbert's Syndrome. J. Gastroenterol. Hepatol. 1999; 14: 960–966
   PubMed Web of Science ®Google Scholar
• Trapnell C.B., Klecker R.W., Jamis-Dow C., Collins J.M. Glucuronidation of 3′-Azido-3′-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid. Antimicrob. Agents Chemother. 1998; 42: 1592–1596
   PubMed Web of Science ®Google Scholar
• Galijatovic A., Walle U.K., Walle T. Induction of UDP-Glucuronosyltransferase by the Flavonoids Chrysin and Quercetin in Caco-2 Cells. Pharm. Res. 2000; 17: 21–26
   PubMed Web of Science ®Google Scholar
• Munzel P.A., Schmohl S., Heel H., Kalberer K., Bock-Hennig B.S., Bock K.W. Induction of Human UDP-Glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-Butylhydroquinone and 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Caco-2 cells. Drug Metab. Dispos. 1999; 27: 569–573
   PubMed Web of Science ®Google Scholar
• Brierley C.H., Senafi S.B., Clarke D., Hsu M.-H., Johnson E.F., Burchell B. Regulation of the Human Bilirubin UDP-Glucuronosyltransferase Gene. Adv. Enzyme Regul. 1996; 36: 85–97
   PubMedGoogle Scholar
• Belanger A., Hum D.W., Beaulieu M., Levesque E., Guillemette C., Tchernof A., Belanger G., Turgeon D., Dubois S. Characterization and Regulation of UDP-Glucuronosyltransferases in Steroid Target Tissues. J. Steroid Biochem. 1998; 65: 301–310
   Google Scholar
• Levesque E., Beaulieu M., Guillemette C., Hum D.W., Belanger A. Effect of Interleukins on UGT2B15 and UGT2B17 Steroid Uridine Diphosphate-Glucuronosyltransferase Expression and Activity in the LNCaP Cell Line. Endocrinology 1998; 139: 2375–2381
   PubMed Web of Science ®Google Scholar
• de Wildt S.N., Kearns G.L., Leeder J.S., van den Anker J.N. Glucuronidation in Humans: Pharmacogenetic and Developmental Aspects. Clin. Pharmacokinet. 1999; 36: 439–452
   PubMed Web of Science ®Google Scholar
• Bouska J.J., Bell R.L., Goodfellow C.L., Stewart A.O., Brooks C.D.W., Carter G.W. Improving the In Vivo Duration of 5-Lipoxygenase Inhibitors. Drug Metab. Dispos. 1997; 25: 1032–1038
   PubMed Web of Science ®Google Scholar
• Houston J.B., Kenworthy K.E. In Vitro–In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis–Menten Model. Drug Metab. Dispos. 2000; 28: 246–254
   PubMed Web of Science ®Google Scholar
• Reisine T., Pasternak G. Opioid Analgesics and Antagonists. Goodman and Gilman's The Pharmacological Basis of Therapeutics, J.G. Hardman, A.G. Gilman, L.E. Limbird. McGraw-Hill, New York 1996; 521–556, Chap. 23
   Google Scholar
• Mistry M., Houston J.B. Glucuronidation In Vitro and In Vivo: Comparison of Intestinal and Hepatic Conjugation of Morphine, Naloxone, and Buprenorphine. Drug Metab. Dispos. 1987; 15: 710–717
   PubMed Web of Science ®Google Scholar
• Bruni S., Chang T.M.S. Kinetic Studies of Hepatocytes UDP-Glucuronosyltransferase: Evidence of an Allosteric Enzyme. Art. Cells Blood Subs. Immob. Biotechnol. 1999; 27: 343–356
   PubMed Web of Science ®Google Scholar
• Beckmann J.D., Henry T., Ulphani J., Lee P. Cooperative Ligand Binding by Bovine Phenol Sulfotransferase. Chem.–Biol. Interact. 1998; 109: 93–105
   PubMed Web of Science ®Google Scholar
• Ekins S., Ring B.J., Binkley S.N., Hall S.D., Wrighton S.A. Autoactivation and Activation of the Cytochrome P450s. Int. J. Clin. Pharmacol. Ther. 1998; 36: 642–651
   PubMed Web of Science ®Google Scholar
• Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzalez F.J., Tracy T.S. Evaluation of Atypical Cytochrome P450 Kinetics with Two-Substrate Models: Evidence that Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites. Biochemistry 1998; 37: 4137–4147
   PubMed Web of Science ®Google Scholar
• Schrag M.L., Wienkers L.C. Topological Alteration of the CYP3A4 Active Site by the Divalent Cation Mg2+. Drug Metab. Dispos. 2000; 28: 1198–1201
   PubMed Web of Science ®Google Scholar
• Jakoby W.B., Ziegler D.M. The Enzymes of Detoxication. J. Biol. Chem. 1990; 265: 20715–20718
   PubMed Web of Science ®Google Scholar
• Shou M., Dai R., Cui D., Korzekwa K.R., Baillie T.A., Rushmore T.H. A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4. J. Biol. Chem. 2001; 276: 2256–2262
   PubMed Web of Science ®Google Scholar
• Weiss J.N. The Hill Equation Revisited: Uses and Misuses. FASEB J. 1997; 11: 835–841
   PubMed Web of Science ®Google Scholar
• Vree T.B., van Dongen R.T.M., Koopman-Kimenai P.M. Codeine Analgesia Is Due to Codeine-6-Glucuronide, Not Morphine. IJCP 2000; 54: 395–398
   Web of Science ®Google Scholar
• Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., Watkins P.B. The Human CYP3A Subfamily: Practical Considerations. Drug Metab. Rev. 2000; 32: 339–361
   PubMed Web of Science ®Google Scholar
• Paine M.F., Khalighi M., Fisher J.M., Shen D.D., Kunze K.L., Marsh C.L., Perkins J.D., Thummel K.E. Characterization of Interintestinal and Intraintestinal Variations in Human CYP3A-Dependent Metabolism. J. Pharm. Exp. Ther. 1997; 283: 1552–1562
   PubMed Web of Science ®Google Scholar
• Iyer L., Hall D., Das S., Mortell M.A., Ramirez J., Kim S., Di Rienzo A., Ratain M.J. Phenotype–Genotype Correlation of In Vitro SN-38 (Active Metabolite of Irinotecan) and Bilirubin Glucuronidation in Human Liver Tissue with UGT1A1 Promoter Polymorphism. Clin. Pharmacol. Ther. 1999; 65: 576–582
   PubMed Web of Science ®Google Scholar
• Lin J.H., Lu A.Y.H. Role of Pharmacokinetics and Metabolism in Drug Discovery and Development. Pharmacol. Rev. 1997; 49: 403–449
   PubMed Web of Science ®Google Scholar
• Guengerich F.P. Pharmacogenomics of Cytochrome P450 and Other Enzymes Involved in Biotransformation of Xenobiotics. Drug Dev. Res. 2000; 49: 4–16
   Web of Science ®Google Scholar